In separate, live virtual events, Neeraj Agarwal, MD, and Alicia Morgans, MD, MPH, discussed options for a patient with metastatic castration-resistant prostate cancer after multiple lines of therapy.
CASE SUMMARY
Clinical work-up:
Treatment and follow-up:
Thirty-six months later:
“What are you most likely to recommend now that the patient’s disease is progressing, with new liver involvement?”
REFERENCE
1. NCCN. Clinical Practice Guidelines in Oncology. Prostate cancer; version 1.2023. Accessed March 3, 2023. https://bit.ly/41DXvHT
Brown Examines Lenvatinib/Pembrolizumab Combination in pMMR Endometrial Cancer
May 17th 2024During a Case-Based Roundtable® event, Jubilee Brown, MD, discussed the efficacy and safety data from the KEYNOTE-775/Study 309 trial of lenvatinib plus pembrolizumab in patients with mismatch repair proficient advanced endometrial cancer.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
How Data Help Physicians Improve Operations and Achieve Health Equity
May 13th 2024A US health care executive survey found 30% see health equity solely as a social concern. Yet, it's about ensuring everyone has a fair shot at optimal health. Utilizing standardized data can shift care from reactive to preventive, easing strain on systems.
Read More